Reviewer’s report

**Title:** Efficacy and Safety of HER2 Inhibitors in Combination With or Without Pertuzumab for HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis

**Version:** 0  **Date:** 10 Jun 2019

**Reviewer:** Wen-Wei Chang

**Reviewer's report:**

The authors performed a good meta-analysis about the efficacy of the combination of pertuzumab or not in HER2+ breast cancer patients from selected 26 studies. The results indicated that the combination with pertuzumab together with trastuzumab related drugs +/- chemotherapy is better than monotherapy for HER2+ breast cancer patients. I think the results are important for the decision for the treatment of HER2+ breast cancer patients. However, the authors should consider to perform further comparison by adding another group of pertuzumab monotherapy to let doctors or patients clearly know the benefits/ adverse effects among these three different treatments. Some other revisions are listed below.

1. Only the arrangement of "Favours no pertuzymab" or "Favours combination" was different in Figure 3. For making consistence through whole manuscript, it is suggested to change the arrangement of Figure 3 as those of other figures.

2. The qualities of figures were poor, even the original uploaded files. It should be improved.

3. The p value of pCR, PFS, OS, or cardiac toxicity should be provided in Abstract section as it was provided for myalgia.

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.

Yes

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

Yes

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.